Considering the large amount of data that is appearing at present, it is plausible that, soon, new groups of patients would benefit from the use of SGLT2 inhibitors or GLP-1-R agonists regardless of T2DM. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.